The Uveitis Treatment Market is expected to foresee significant growth. The U.S. to lead the growth!
- Vikas Kumar
- July 16, 2022
- Uveitis Treatment Market, Uveitis Treatment Market Forecast, Uveitis Treatment Market Growth, Uveitis Treatment Market Report, Uveitis Treatment Market Share, Uveitis Treatment Market size, Uveitis Treatment Market Trend
- 0 Comments
The Uveitis Treatment Market is expected to witness a CAGR of around 6% during the forecast period. Uveitis is a form of eye inflammation that affects the middle layer of tissue in the eye wall (uvea). Some of the symptoms include redness, pain, light sensitivity, blurred vision, and dark floating spots in the field of vision. Possible causes of uveitis are infection, injury, or an autoimmune or inflammatory disease. Uveitis can be serious, leading to permanent vision loss. Thus, early diagnosis and treatment play a pivotal role in preventing serious complications and preserving patients’ vision. Moreover, according to an article published by the Ocular Immunology and Uveitis Foundation in April 2022, uveitis afflicts 109,000 people in the U.S. and 43,000 new cases are diagnosed annually. Thus, uveitis treatment to witness a steady rise during the forecast period.
The COVID-19 outbreak will impact the uveitis treatment market in the initial phase of 2020. Due to nationwide lockdowns and restrictions on movement across the globe. The market registered a certain decline during the pandemic as ophthalmology was one of the most impacted specialties in the field of medicine, with severe curtailing of some practices and permission for carrying out only the most urgent procedures. However, as the COVID-19 cases declined in the latter half of 2020, healthcare providers and patients started taking necessary precautions and the uveitis treatment market witnessed a steady rise.
For a detailed analysis of the Uveitis Treatment Market browse through https://univdatos.com/report/uveitis-treatment-market/
Based on drug class, the uveitis treatment market is segmented into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. The anti-inflammatory category is anticipated to witness a significant growth rate during the forecast period. The growth of this drug category ismainly due to the increasing cases of non-infectious eye diseases such as eye redness or pain, light sensitivity, blurred vision, etc. Further, major players in the market are increasing their focus on developing and launching new drugs for the treatment of uveitis. For instance, in March 2022, Bausch + Lomb and Clearside Biomedical launched “xipere” (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with anterior, intermediate, posterior, or pan uveitis in the U.S.
Based on disease type, the uveitis treatment market is segmented into anterior uveitis, posterior uveitis, intermediate uveitis, and pan uveitis. The anterior uveitis category is anticipated to witness a significant growth rate during the forecast period. The growth of this category ismainly due to the high risk for people with untreated anterior uveitis leading to loss of vision as well as the development of cataract, glaucoma, or retinal edema coupled with the growing geriatric population. For instance, according to World Health Organization (WHO), around 253 million people across the globe live with vision impairment; of which, about 36 million are blind and 217 million suffer from moderate or severe vision impairment.
Based on distribution channel, the uveitis treatment market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. In 2020, the hospital pharmacies category is anticipated to witness a significant growth rate during the forecast period. Moreover, treatment of infectious or non-infectious eye diseases, such as cataracts, band keratopathy, cystoid macular edema, and autoimmune & inflammatory illnesses are performed in hospitals. For instance, according to the United Nations, the 60+ aged population was 962 million in 2017 and the number of the elderly population is expected to double again by 2050 and reach nearly 2.1 billion worldwide.
Request for Sample of the report browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=22860
For a better understanding of the market, the report provides a detailed analysis of major regions and countries including North America (U.S., Canada, Rest of America); Europe (Germany, U.K., France, Spain, Italy, Rest of Europe); Asia-Pacific (China, India, Japan, Rest of Asia-Pacific) and Rest of World. In 2020, North America accounted for a significant market share. This is mainly due to the increasing patient pool in the hospitals, rising cases of cystoid macular edema, and autoimmune & inflammatory illnesses. Furthermore, with high consumer spending on healthcare coupled with supportive reimbursement policies and advanced healthcare infrastructure, the region’s market is to witness significant during the forecast period.
Some of the major companies operating in the uveitis treatment market include AbbVie Inc., Alimera Sciences Inc., Allergan Plc., Amgen Inc., Bausch Health Companies Inc., Clearside Biomedical Inc., EyePoint Pharmaceuticals Inc., Mylan N.V., Novartis AG, and Santen Pharmaceutical Co. Ltd.
Uveitis Treatment Market Segmentation
Market Insight, By Drug Class
• Antimicrobial Drugs
• Immunotherapy & Targeted Therapies
Market Insight, By Diseases Type
• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Pan uveitis
Market Insight, By Distribution Type
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online pharmacies
Market Insight, By Region
- North America Uveitis Treatment Market
- Rest of America
- Europe Uveitis Treatment Market
- Rest of Europe
- Asia-Pacific Uveitis Treatment Market
- Rest of Asia-Pacific
- Rest of the world Uveitis Treatment Market
Top Company Profiles
• AbbVie Inc.
• Alimera Sciences Inc.
• Allergan Plc.
• Amgen Inc.
• Bausch Health Companies Inc.
• Clearside Biomedical Inc.
• EyePoint Pharmaceuticals Inc.
• Mylan N.V.
• Novartis AG
• Santen Pharmaceutical Co. Ltd.